Biodesix Inc(BDSX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.17 | Insider Own | 55.58% | Shs Outstand | 10.6M | Perf Week | -8.04% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | 37.54% | Insider Trans | 0.73% | Shs Float | 4.7M | Perf Month | -27.84% |
| Enterprise Value | 0.27B | PEG | - | EPS next Q | -0.75 | Inst Own | 41.34% | Short Float | 4.47% | Perf Quarter | 7.7% |
| Income | -0.03B | P/S | 2.25 | EPS this Y | 42.8% | Inst Trans | 3.62% | Short Ratio | 2.07 | Perf Half Y | 120.6% |
| Sales | 0.10B | P/B | 25.32 | EPS next 5Y | 39.91% | ROA | -30.33% | Short Interest | 0.21M | Perf YTD | 222.79% |
| Book/sh | 0.87 | P/C | 7.69 | EPS past 3/5Y | 46.84% 27.68% | ROE | -540.01% | 52W High | -31.34% ($31.97) | Perf Year | 230.08% |
| Cash/sh | 2.85 | P/FCF | - | Sales past 3/5Y | 32.31% 14.2% | ROIC | -35% | 52W Low | 317.3% ($5.26) | Perf 3Y | -21.04% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.48% | Gross Margin | 82.5% | Volatility(W/M) | 8.16% 7.6% | Perf 5Y | -84.76% |
| Dividend TTM | - | EV/Sales | 2.65 | Sales Y/Y TTM | 34.46% | Oper. Margin | -19.99% | ATR (14) | 1.86 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.77 | EPS Q/Q | 54.83% | Profit Margin | -26.97% | RSI (14) | 35.4 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.85 | Sales Q/Q | 34.18% | SMA20 | -12.65% ($25.13) | Beta | 0.63 | Target Price | $39 |
| Payout | - | Debt/Eq | 7.86 | Earnings | 2026/11/5 | SMA50 | -17.11% ($26.48) | Rel Volume | 1.4 | Prev Close | $21.26 |
| Employees | 334 | LT Debt/Eq | 7.68 | EPS/Sales Surpr. | 21.27% 3.21% | SMA200 | 18.97% ($18.45) | Avg Volume(3M) | 0.10M | Price | $21.95 |
| IPO | 2020/10/28 | Option/Short | No/Yes | Trades | 1289 | Volume | 141,687 | Change | 3.25% |
🫁 A US-based molecular diagnostics company specializing in tests for lung disease diagnosis. It operates a portfolio of blood-based diagnostic tests designed to help with the early detection of lung nodules and lung cancer, and also provides biomarker analysis services for pharmaceutical companies. It is classified as a precision diagnostics specialist focused on the lung health segment.
Over the past 1 year, roughly in the middle
31% below its 1-year high.
Traded more than usual. That is 140% of its average volume.
Next earnings report: November 5
8 days to go.
BDSX has weak earnings and a weak balance sheet
Of every $100 in sales, $19.99 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +42.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $225. Peers typically go for $451.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -84.8%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 41.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #33 of 44 in the industry
Based on market cap of $232M.
FAQ
What kind of company is BDSX?
BDSX belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of BDSX?
The market cap of BDSX is approximately $232M, ranking 3,900 within its sector.
What is the 52-week high and low for BDSX?
BDSX has recorded a 52-week high of $31.97 and a low of $5.26.
